Timp-3 mediates T cell-B cell collaboration by inhibitinp ADAM17/TACE-mediated shedding of CD154. by Blumenkron, F, Phillips, T, Fischer, R, Lugar, P, Withers, D, Pavlovitch, C, Nagase, H, Lipsky, P, Grammer, A

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase I... by Maini, R, St Clair, E, Breedveld, F, Furst, D, Kalden, J, Weisman, M, Smolen, J, Emery, P, Harriman, G, Feldmann, M, Lipsky, P

Infliximab and methotrexate in the treatment of rheumatoid arthritis by Lipsky, P, Van Der Heijde, D, St Clair, E, Furst, D, Breedveld, F, Kalden, JR, Smolen, J, Weisman, M, Emery, P, Feldmann, M, Harriman, G, Maini, R

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. by Lipsky, P, van der Heijde, D, St Clair, E, Furst, D, Breedveld, F, Kalden, JR, Smolen, J, Weisman, M, Emery, P, Feldmann, M, Harriman, G, Maini, R

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). by Furst, D, Breedveld, F, Burmester, G, Crofford, J, Emery, P, Feldmann, M, Kalden, JR, Kavanaugh, A, Keystone, E, Klareskog, L, Lipsky, P, Maini, R, Russell, A, Scott, D, Smolen, J, Van de Putte, L, Visher, T, Weisman, M